Casdin Capital KYTX Position
Exited8-Fund ConvergenceCasdin Capital exited their position in Kyverna Therapeutics, Inc. (KYTX) in Q3 2024, after holding the stock for 3 quarters.
The position was first reported in Q1 2024 and has been tracked across 3 quarterly 13F filings.
KYTX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.2% of float with 7.2 days to cover, indicating significant bearish positioning against the stock.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Full company profile →Short Interest
10.2%
7.2 days to cover
Casdin Capital KYTX Position History
Frequently Asked Questions
Does Casdin Capital own KYTX?
No. Casdin Capital exited their position in Kyverna Therapeutics, Inc. (KYTX) in Q3 2024. They previously held the stock for 3 quarters.
How many hedge funds own KYTX?
8 specialist biotech hedge funds currently hold KYTX, including RTW Investments, Deerfield Management, Commodore Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy KYTX?
Casdin Capital's position in KYTX was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's KYTX position increasing or decreasing?
Casdin Capital completely exited their KYTX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KYTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →